Land: Canada
Taal: Engels
Bron: Health Canada
CLINDAMYCIN (CLINDAMYCIN PHOSPHATE)
BAXTER CORPORATION
J01FF01
CLINDAMYCIN
600MG
SOLUTION
CLINDAMYCIN (CLINDAMYCIN PHOSPHATE) 600MG
INTRAVENOUS
15G/50G
Prescription
LINCOMYCINS
Active ingredient group (AIG) number: 0105830009; AHFS:
APPROVED
2019-02-04
_Clindamycin Injection in 5% Dextrose_ _Page 1 of 33 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR CLINDAMYCIN INJECTION IN 5% DEXTROSE Ready-to-use bags, clindamycin 6 mg / mL (300 mg / 50 mL), 12 mg / mL (600 mg / 50 mL) and 18 mg / mL (900 mg / 50 mL) (as clindamycin phosphate) STERILE SOLUTION ANTIBIOTIC Baxter Corporation 7125 Mississauga Road Mississauga, Ontario L5N 0C2 Date of Revision: February 1, 2019 Submission Control No: 212923 Baxter and GALAXY are trademarks of Baxter International Inc. _Clindamycin Injection in 5% Dextrose_ _Page 2 of 33 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .......................................................... 3 SUMMARY PRODUCT INFORMATION .......................................................................... 3 INDICATIONS AND CLINICAL USE ................................................................................ 3 CONTRAINDICATIONS ..................................................................................................... 5 WARNINGS AND PRECAUTIONS .................................................................................... 5 ADVERSE REACTIONS ...................................................................................................... 8 DRUG INTERACTIONS .................................................................................................... 10 DOSAGE AND ADMINISTRATION ................................................................................ 11 OVERDOSAGE ................................................................................................................... 13 ACTION AND CLINICAL PHARMACOLOGY .............................................................. 13 STORAGE AND STABILITY ............................................................................................ 15 SPECIAL HANDLING INSTRUCTIONS ......................................................................... 15 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................. 16 Lees het volledige document